AVBCC

Currently, 31 biosimilar products have been approved by the FDA, 20 of which have been launched in the United States. As the biosimilar markets become more competitive, so should pricing, said Sean McGowan, Senior Director, Biosimilars, AmerisourceBergen, Philadelphia, PA, who moderated a panel discussion on the gateway and watershed opportunities ahead for biosimilars and their adoption in oncology at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021. Read More ›

Oncologic drug pricing is being transformed with greater value in mind. At the 11th Annual Summit of the Association for Value-­Based Cancer Care in 2021, a panel led by moderator William McGivney, PhD, Managing Principal, McGivney Global Advisors, Wayne, PA, discussed innovation in drug pricing, how the current rebate system supports higher drug costs, balancing new interventions with profits, and the implications of drug price negotiations being considered in Congress. Read More ›

At the 11th Annual Summit of the Association for Value-­­Based Cancer Care in 2021, health plans and employers discussed the utility of value-­based contracting for managing oncology care costs while maintaining focus on outcomes of value for patients. Rob O’Brien, Vice President, Specialty, Real Endpoints, Florham Park, NJ, served as moderator for this session. Read More ›

The use of telehealth in the fee-for-service program surged by more than 4000% during the first 6 months of the COVID-19 pandemic. Read More ›